In the management of lipid lowering after a myocardial infarction, which drug class is considered first-line for lipid lowering?

• A. ACE inhibitors
• B. Statins
• C. Beta-blockers
• D. Thiazide diuretics

Answer: (B)

The main idea is that statins are the go-to therapy for lowering lipids after a myocardial infarction because they not only lower LDL cholesterol strongly, but also consistently reduce recurrent cardiovascular events in people with established coronary disease. Statins work by inhibiting HMG-CoA reductase, which lowers the liver’s production of cholesterol, leading to substantial decreases in LDL. Beyond the numbers, they have plaque-stabilizing and anti-inflammatory effects that help prevent further events.

In clinical practice, high-intensity statin therapy is recommended after MI (for example, atorvastatin or rosuvastatin at higher doses) to achieve a substantial LDL reduction, often aiming for a 50% or greater drop and/or an LDL level below about 70 mg/dL in very high-risk patients. This approach is supported by large trials and guidelines showing improvements in survival and fewer recurrent heart events.

The other drugs listed have important roles in post-MI care—ACE inhibitors help with heart remodeling and blood pressure control, beta-blockers reduce mortality and arrhythmia risk, and thiazide diuretics help with blood pressure and fluid balance—but they do not provide the primary lipid-lowering effect that statins offer.